IBB240705P136500
- 0.87
- -0.93-51.67%
iShares Biotechnology ETF Newsroom
Study Links GLP-1 Drugs, Metformin to Lower Risk of Certain Cancers
Unpacking the Latest Options Trading Trends in Moderna
Investors with a lot of money to spend have taken a bullish stance on Moderna (NASDAQ:MRNA).And retail traders should know.We noticed this today when the trades showed up on publicly available options
Sector Update: Health Care Stocks Steady Premarket Friday
Health care stocks were steady premarket Friday, with the Health Care Select Sector SPDR Fund (XLV) and iShares Biotechnology ETF (IBB) inactive. Bain Capital and Cinven are considering a potential jo
Exchange-Traded Funds Edge Higher, Equity Futures Mixed Pre-Bell Friday as Investors Await Hints About Potential Rate Cuts
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.04% and the actively traded Invesco QQQ Trust (QQQ) was 0.1% higher in Friday's premarket activity, as investors wait for th
AI Has 'The Hallmarks Of An Inflating Bubble,' Warns Veteran Wall Street Investor
Signs are emerging that the market boom surrounding artificial intelligence (AI) might be taking on the characteristics of a bubble.
Here's How Much $1000 Invested In Moderna 5 Years Ago Would Be Worth Today
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 37.68% on an annualized basis producing an average annual return of 50.84%. Currently, Moderna has a market capitalization of
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,300 Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 10 years by 1.82% on an annualized basis producing an average annual return of 12.66%. Currently, Regeneron Pharmaceut
Lilly's New Alzheimer's Drug Could Generate $7.1B in Sales: Analyst
S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for rate cuts following June's sharply lower-than-expected services sector activ
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
On Tuesday, the FDA approved Eli Lilly and Co's (NYSE:LLY) Kisunla (donanemab) once-monthly injection for IV infusion) for adults with early symptomatic Alzheimer's disease.Once-monthly, Kisunla is th
What's Going On With Moderna Stock Wednesday
Moderna, Inc. (NASDAQ:MRNA) shares are trending on Wednesday.
Sector Update: Health Care Stocks Steady Pre-Bell Wednesday
Health care stocks were steady pre-bell Wednesday as the Health Care Select Sector SPDR Fund (XLV) and iShares Biotechnology ETF (IBB) were inactive recently. CureVac (CVAC) and GSK (GSK) said they re
Alnylam Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/03/2024 0.4% JP Morgan $160 → $248 Maintains Neutral 07/01/2024 -39.27% Cantor Fitzgerald $150 → $150 R
Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
On Wednesday, the European Medicines Agency (EMA) approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characteriz
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday Ahead of Economic Data Deluge
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was flat and the actively traded Invesco QQQ Trust (QQQ) was 0.03% lower in Wednesday's premarket activity as markets traded mixed ah
Looking Into Regeneron Pharmaceuticals's Recent Short Interest
Regeneron Pharmaceuticals's (NYSE:REGN) short percent of float has risen 5.99% since its last report. The company recently reported that it has 1.85 million shares sold short, which is 1.77% of all re
What the Options Market Tells Us About Amgen
Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen (NASDAQ:AMGN) revealed 9 unusual trades.Delving into the details, we found 11% of traders were
Eli Lilly Wins FDA Approval of Donanemab for Alzheimer's
MRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment
The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame during the COVID-19 pandemic. The beauty of mRNA technology is that it opens
COVID Infections Could Be Seeing a Summer Surge Based on CDC Data